Gilead to Test a Version of Remdesivir That Can Be Inhaled
The New York Times published on June 22, 2020: The American biopharmaceutical company Gilead Sciences will soon start trials of
Tag: remdesivir
Gilead to Initiate Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years
Set-up of an upcoming clinicl trial has been posted with the primary objectives of this study are to evaluate the
A new country to approve remdesivir for COVID-19 treatment: Israel
Israel approved on Tuesday the use of Gilead Sciences Inc’s antiviral drug remdesivir for the treatment of patients with COVID-19
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
In a pandemic like Covid-19 the urgent need excludes the development of new drugs, “conventional drug in new use” becomes
Eva Pharma, DRL, Biocon and Zydus Cadila added to Voluntary Licensing Agreements for Remdesivir
Gilead has signed non-exclusive voluntary licensing agreements with further generic pharmaceutical manufacturers based in Egypt and India to further expand supply
Conditional approval of Veklury® (SBECD-enabled remdesivir) for COVID-19 infection in Singapore
The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee and infectious diseases experts informed healthcare professionals on
ALL EYES ON GILEAD
Bloombergs Businessweek published the story on how Gilead scineces prepared for the recently obtained emergency approval of the antiviral drug
Ligand CEO Issues Letter to Captisol Customers
Yesterday, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The
Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
Gilead Sciences, Inc. announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This
UK grants early access for Gilead’s remdesivir in Covid-19
The government of the U.K. is granting the country’s equivalent to an emergency use authorization to remdesivir, the antiviral drug